Portal de investigación
Use of anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses.
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Morgado-Carrasco D
Grupos
Abstract
Anifrolumab is an inhibitor of the type I interferon receptor subunit 1 (IFNAR1) recently approved for the management of moderate-to-severe systemic lupus erythematosus (SLE). In 2 clinical trials, it has proven effective to treat cutaneous signs. Although anifrolumab has not been indicated for cutaneous lupus erythematosus (CLE), multiple cases and case series (20 publications with a total of 78 patients) have shown good and rapid responses with this drug, both in subacute CLE and discoid lupus erythematosus, as well as in lupus panniculitis and perniosis. Two case reports of dermatomyositis have also experienced clinical improvement with anifrolumab. Clinical trials of this drug are ongoing for subacute CLE and discoid lupus erythematosus, systemic sclerosis, and progressive vitiligo. Its most common adverse effects are respiratory infections and herpes zoster. Anifrolumab may be a well-tolerated alternative in the management of CLE.
Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 0001-7310, 1578-2190
- Tipo:
- Article
- Páginas:
- 55-67
- PubMed:
- 38972582
- Factor de Impacto:
- 0,279 SCImago ℠
- Cuartil:
- Q3 SCImago ℠
Actas dermo-sifiliograficas ELSEVIER ESPANA S I
Documentos
- No hay documentos
Filiaciones
Proyectos y Estudios Clínicos
Análisis de la utilidad e indicaciones del cribado de cáncer cutáneo en pacientes sometidos a trasplante de progenitores hematopoyéticos.
Investigador Principal: RAFAEL BOTELLA ESTRADA
CC-TPH . 2023
Espaciamiento de la dosis de dupilumab en dermatitis atópica: serie de casos.
Investigador Principal: RAFAEL BOTELLA ESTRADA
DUPI300Q3/4W . 2023
Caracterización y evolución de los pacientes con hidrosadenitis supurativa tratados con fármacos biológicos o de pequeña molécula diferentes a adalimumab en un hospital de tercer nivel.
Investigador Principal: RAFAEL BOTELLA ESTRADA
HS-BIO . 2023
Uso de tirbanibulina para el tratamiento del queratosis actínicas y campo de cancerización.
Investigador Principal: RAFAEL BOTELLA ESTRADA
TIFAKS . 2023
Cita
MARTÍN D,MANSILLA M,Morgado D. Use of anifrolumab in systemic lupus erythematosus, cutaneous lupus erythematosus, and other autoimmune dermatoses. Actas Dermo-Sifilogr. 2025. 116. (1):p. 55-67.